The treatment was developed in this study through the use of some cell lines, and established that the simultaneous inhibition of AXL, Mammalian target of rapamycin (mTOR) and EGFR were decisive in increasing IFNγ levels by decreasing the progression of cancer cells and stimulating the tumor environment to be more responsive to glioblastoma cells [96]. This evidence concerns the gene EGFR and glioblastoma.